arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Sensei Biotherapeutics, Inc.

FTH

$24.30 ▲ +0.17 (+0.70%) at close

7 Visible periods

23 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Sensei Biotherapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $30.6M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -119.9% ↘

FCF / Share $-16.24 ↗

Trailing P/E —

Price / Book 1.7x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-21.09M

↑ +30.1% —

FCF / Share Free cash flow per share

$-16.24

↑ +17.8% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Financial Health ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
EPS Growth YoY (%)	30.4% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	1.6% Caution ↓ Caution Declining Year-over-year change in earnings per share Optimal: > 10%	22.8% Good Good Year-over-year change in earnings per share Optimal: > 10%	-18.8% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	30.1% Excellent ↑ Excellent Improving Year-over-year change in net income	11.6% Fair ↑ Fair Improving Year-over-year change in net income	29.8% Excellent ↑ Excellent Improving Year-over-year change in net income	-32.1% Weak Weak Year-over-year change in net income	-83.1% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	17.8% Good ↑ Good Improving Year-over-year change in free cash flow	14.2% Fair ↑ Fair Improving Year-over-year change in free cash flow	10.1% Fair Fair Year-over-year change in free cash flow	-10.0% Weak Weak Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Effective Tax Rate (%) (%)	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—
FCF / Net Income (x)	0.97x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.81x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-119.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-85.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-45.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-38.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-20.2% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	27.5% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-97.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-71.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-49.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-42.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-24.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	-90.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-113.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-856%)	-78.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-624%)	-52.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-450%)	-47.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-413%)	-25.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-267%)	35.6% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+137%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Debt to Equity (x)	—	—	—	—	—	-0.01x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-102%)	—
Interest Coverage (x)	-696.50x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-362.38x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-257.39x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-229.17x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-55.94x Weak Weak Operating income divided by interest expense Optimal: > 5x	-11.52x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-8.67M	$-9.99M	$-13.01M	$-17.80M	$-7.16M	$-16.03M	—
Debt / EBITDA (x)	—	—	—	—	—	-0.03x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Basic EPS, GAAP (USD)	$-16.72	$-24.01	$-24.40	$-31.60	$-26.60	—	—
Free Cash Flow per Share (USD)	$-16.24	$-19.76	$-23.04	$-25.63	$-23.30	—	—
Book Value per Share (USD)	$14.74	$30.49	$51.85	$67.23	$95.73	$-601.92	—
Tangible Book Value per Share (USD)	$14.74	$30.49	$51.85	$67.23	$95.73	$-601.92	—
Basic Weighted Avg Shares (shares)	1.26M	1.26M	1.40M	1.54M	1.39M	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$17.26M	$36.48M	$61.61M	$99.52M	$143.65M	$15.25M	—
LT Debt (USD)	—	—	—	—	—	$567.00K	—
Total Equity (USD)	$18.59M	$38.39M	$64.89M	$103.41M	$146.51M	$-56.44M	$-68.66M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Depreciation Expense (USD)	$122.00K	$551.00K	$571.00K	$614.00K	$685.00K	$209.00K	—
Net Income, GAAP (USD)	$-21.09M	$-30.16M	$-34.10M	$-48.59M	$-36.79M	$-20.10M	—
Operating Cash Flow (USD)	$-20.45M	$-24.67M	$-32.02M	$-39.03M	$-30.26M	$-17.70M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters

Sensei Biotherapeutics, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare FTH with peers